Camrelizumab and Apatinib for Neoadjuvant Therapy in Thyroid Cancer
Status:
Not yet recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
To determine the efficacy and safety of anti-PD-1 antibody Camrelizumab combined with
Apatinib for neoadjuvant therapy in locally advanced thyroid cancer.